Coudeville Laurent, Bertrand-Gerentes Isabelle, Zocchetti Céline, Langevin Edith, Bchir Siham, Coste Florence, Oster Philipp
Global Medical, Sanofi Vaccines, 14 Espace. Henry Vallée, 69007, Lyon, France.
Global Biostatistical Sciences, Sanofi Vaccines, Marcy L'Étoile, France.
Sci Rep. 2025 Jul 10;15(1):24990. doi: 10.1038/s41598-025-08112-0.
Evaluating the persistence of antibody titers produced by quadrivalent meningococcal vaccines is crucial for determining the optimal timing for primary and booster doses. Using 3 - 7-year persistence data after a single priming dose of MenACYW-TT to fit a statistical model of antibody decay over time (10 years), this analysis modeled long-term antibody persistence for this vaccine in toddlers (12-23 months), adolescents/young adults (13-26 years), and older adults (≥ 56 years), comparing it with other vaccines (MCV4-TT, MenACWY-CRM, MPSV4). The statistical model is based on a Bayesian approach and it accounts for vaccine- and age group-specific antibody decline, missing data, assay errors, and antibody boosting from breakthrough infections. At 10 years post-vaccination, it predicted comparable or higher seroprotective immunopersistence for MenACYW-TT (titers ≥ 1:8 with hSBA) versus (1) MCV4-TT in toddlers (77% [95% CI 70-84] vs. 17% [6-31] for serogroup C, 67% [59-74] vs. 36% [20-53] for serogroup W); (2) MenACWY-CRM in adolescents/young adults (63% [55-71] vs. 40% [32-48] for serogroup C, 67% [59-74] vs. 57% [47-67] for serogroup W); and (3) MPSV4 in older adults (31% [23-39] vs. 22% [14-29] for serogroup C, 38% [31-46] vs. 20% [14-27] for serogroup W). In conclusion, our analysis indicated similar or higher immune persistence at 10 years for MenACYW-TT compared with other quadrivalent meningococcal vaccines, particularly for serogroups C and W.
评估四价脑膜炎球菌疫苗产生的抗体滴度持久性对于确定初免和加强剂量的最佳时间至关重要。利用单剂次MenACYW-TT初免后3至7年的持久性数据来拟合随时间（10年）抗体衰减的统计模型，本分析模拟了该疫苗在幼儿（12至23个月）、青少年/青年（13至26岁）和老年人（≥56岁）中的长期抗体持久性，并与其他疫苗（MCV4-TT、MenACWY-CRM、MPSV4）进行比较。该统计模型基于贝叶斯方法，考虑了疫苗和年龄组特异性的抗体下降、缺失数据、检测误差以及突破性感染引起的抗体增强。在接种疫苗后10年，该模型预测MenACYW-TT（hSBA法滴度≥1:8）具有相当或更高的血清保护性免疫持久性，与以下情况相比：（1）幼儿中的MCV4-TT（C群：77%[95%CI 70-84]对17%[6-31]，W群：67%[59-74]对36%[20-53]）；（2）青少年/青年中的MenACWY-CRM（C群：63%[55-71]对40%[32-48]，W群：67%[59-74]对57%[47-67]）；（3）老年人中的MPSV4（C群：31%[23-39]对22%[14-29]，W群：38%[31-46]对20%[14-27]）。总之，我们的分析表明，与其他四价脑膜炎球菌疫苗相比，MenACYW-TT在10年时具有相似或更高的免疫持久性，尤其是针对C群和W群。
